RxDoctor Payments Data

Heather Lee

Nurse Practitioner · Key West, FLNPI 1578938338

Payments from drug & device makers

$6,107in general payments, 2019–2025

Across 227 payments — averaging $26.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Gilead$393
  • Astellas Pharma US Inc$374
  • AbbVie$342
  • Seagen Inc.$337
  • Lilly USA, LLC$311
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$4,97381%
  • Education$1,13519%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,107 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$100,634
Medicare patients
308
Services billed
1,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate25$511,585
OjjaaraMomelotinib Dihydrochloride16$459,492
ErleadaApalutamide31$433,072
BrukinsaZanubrutinib26$407,443
TepmetkoTepotinib Hcl12$305,631
RetevmoSelpercatinib12$279,306
TagrissoOsimertinib Mesylate13$226,341
VerzenioAbemaciclib13$208,873
XtandiEnzalutamide15$205,497
ImbruvicaIbrutinib13$200,098
EliquisApixaban215$172,352
TasignaNilotinib Hcl13$130,319
CalquenceAcalabrutinib Maleate13$109,779
XareltoRivaroxaban79$79,304
Abiraterone Acetate14$52,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Xarelto$216$512,377110 claims
Incyte CorporationJakafi$224$511,58525 claims
Lilly USA, LLCRetevmo, Verzenio$311$488,17925 claims
GSKOjjaara$114$459,49216 claims
AstraZenecaTagrisso, Calquence$198$336,12026 claims
EMD Serono, Inc.Tepmetko$117$305,63112 claims
Astellas Pharma US IncXtandi$374$205,49715 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$71$200,09813 claims
PfizerEliquis$225$172,352215 claims
NovartisTasigna$1,030$130,31913 claims
AbbVieCreon$342$51,10413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Key West

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →